3
Silexion Therapeutics Corp. (NASDAQ:SLXN) released data on Wednesday from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces primary tumor growth and metastatic spread.
These findings significantly advance over previously reported data by validating SIL204’s efficacy in the more clinically relevant orthotopic setting, where human pancreatic tumor cells are implanted directly into the pancreas to better mimic human disease progression.
Also Read: Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Key New Findings
- SIL204 administered subcutaneously (systemically) showed …
